CAR-T cell therapies administered in an outpatient setting may be safe and feasible without intensive remote monitoring in hematologic malignancies. Receiving CAR-T cell therapies in an outpatient ...
The following is a summary of “Impact of critical illness on continuation of anticancer treatment and prognosis of patients with aggressive hematological malignancies,” published in the September 2024 ...